ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma

Conditions:   Immunotherapy;   Head and Neck Neoplasms
Intervention:   Drug: Nivolumab with or without Ipilimumab
Sponsor:   The Netherlands Cancer Institute
Not yet recruiting - verified December 2016

http://ift.tt/2hNuAKU